Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer

Lung cancer has become a global health issue in recent decades. Approximately 80-85% of cases are non-small-cell lung cancer (NSCLC). Despite the high rate of resistance, cisplatin-base chemotherapy is still the main treatment for NSCLC patients. Thus, overcoming cisplatin resistance is urgently nee...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Qian, Ji, Qinghong, Zhang, Ying, Ma, Weihong, Tian, Baoqing, Liu, Yanli, Chen, Yunsong, Wang, Fei, Zhang, Ran, Wang, Xingwu, Yuan, Jupeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236771/
https://www.ncbi.nlm.nih.gov/pubmed/35770045
http://dx.doi.org/10.1155/2022/1112987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236771/
https://www.ncbi.nlm.nih.gov/pubmed/35770045
http://dx.doi.org/10.1155/2022/1112987

Ejemplares similares